{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-185087","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2022-06-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.816775+00:00","generated_at":"2026-06-24T22:24:41.953928+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"AVROBIO CSO Christopher Mason to depart June 30; option exercise period extended to 12 months","bullets":["Chief Scientific Officer Christopher Mason's employment ends June 30, 2022 per prior agreement.","Compensation committee extended post-termination exercise period for his time-based stock options and equity awards from 3 to 12 months.","Company also updated its corporate slide presentation for investor meetings; no new specific data disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-185087","json":"https://secwatch.observer/filing/0001193125-22-185087.json","markdown":"https://secwatch.observer/filing/0001193125-22-185087.md","text":"https://secwatch.observer/filing/0001193125-22-185087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000119312522185087/0001193125-22-185087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000119312522185087/d374875d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T22:24:41.953928+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4d0e51a834","claim":"Christopher Mason was terminated as Chief Scientific Officer at Tectonic Therapeutic, Inc..","evidence_excerpt":"As previously disclosed, Dr. Mason’s employment with the Company will terminate on June 30, 2022 pursuant to the terms of his employment agreement, as amended.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681087/000119312522185087/0001193125-22-185087-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}